3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Neoplasms
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Urinary Bladder Neoplasms
1
Solid Tumor
1
Ovarian Neoplasms
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
NSCLC
1
Myeloproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid
1
Leukemia
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Glioblastoma
1
Bone Marrow Diseases
1
Advanced Solid Tumor
1
Adenocarcinoma of Lung
1
Interventions
ulixertinib
1
tislelizumab
1
talazoparib
1
serabelisib
1
sapanisertib
1
pembrolizumab
1
olaparib
1
mirdametinib
1
lenvatinib
1
erdafitinib
1
crenigacestat
1
atezolizumab
1
Ramucirumab
1
Paclitaxel
1
PM 01183
1
Injections
1
IFL protocol
1
Gemcitabine
1
Bosentan
1
BID protein, human
1
Appointments and Schedules
1
1-dodecylpyridoxal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Advanced Solid Tumor
×
BID protein, human
×
Clear all
NCT06560632
2026-01-16
POLAR
Repare Therapeutics
Phase 1
Terminated
26 enrolled
14 charts